Why McKesson Stock Soared More Than 5% Higher Today

McKesson (NYSE:MCK) investors received a strong dose of good news on the second-to-last trading day of the week. The storied pharmaceutical and healthcare products distributor announced the extension of its partnership with a major pharmacy chain operator. This development pushed McKesson stock to an over 5% gain on Thursday.

Long-standing partnership

McKesson's counterparty is none other than the ubiquitous CVS Health (NYSE:CVS). The two companies have signed an agreement in principle for the former to distribute medicines to mail-order, specialty, and retail pharmacies, as well as distribution centers, through June 2032.

In the press release trumpeting the new arrangement, McKesson quoted CEO Brian Tyler as saying that "We are pleased to extend our long-standing, strategic relationship with CVS Health and continue supporting their important role in serving patients and communities across the country."

McKesson didn't hesitate to mention that the extension builds on a 25-year history between it and CVS.

Guidance maintained

With one important item ticked off its to-do list, McKesson was confident enough to reiterate its guidance for the current fiscal year (2027). It' still believes its net income not under generally accepted accounting principles (non-GAAP, or adjusted) will hit $44.20 to $45 per share. The company also reaffirmed its long-term forecast of 13% to 16% growth in adjusted, per-share earnings.

McKesson is a go-to distributor in its field, a longtime operator that many partners trust to get medicines and other supplies where they need to go. That's a solid advantage in an environment where the U.S. population is aging proportionally, thereby requiring more medical care and products. The company's stock is a fine play on this dynamic.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends CVS Health and McKesson. The Motley Fool has a disclosure policy.